Investigational. In clinical development, not approved. Material sold as a research chemical is not the trial drug. Educational only — not medical advice.
What it is
Survodutide is a dual GLP-1 / glucagon receptor agonist studied in obesity and, notably, MASH (fatty liver disease).
Proposed mechanism
Like mazdutide, it pairs GLP-1 agonism with glucagon-receptor agonism; the glucagon arm is of particular interest for liver-fat reduction.1
State of the evidence
Positive Phase 2 (incl. MASH); Phase 3 ongoing; not approved.
Regulatory & status
Investigational; not approved.
Reconstitution (reference only)
Lab-handling reference only — not a preparation or dosing instruction: 1.5 mL (150 units) reconstitution solution per 10 mg vial. See the reconstitution calculator for the arithmetic. This page does not provide dosing guidance.
References
GLP-1/glucagon dual agonists in MASH/obesity (literature). PubMed: survodutide
This free reference is made possible by our sponsor, PureLux Bio — U.S.-made research-grade peptides.
For educational and research purposes only. This content is not medical advice. Compounds referenced are research use only and not intended to diagnose, treat, cure, or prevent any disease. Free Peptide University does not sell compounds.